T cell proliferative responses to five human cytomegalovirus proteins in healthy seropositive individuals: implications for vaccine development

References

1. Alp J. A., Allport T. D., Zanten J. V., Rodgers B., Sissons J. G. P., Borysiewicz L. K. 1991; Fine specificity of cellular immune responses in humans to human cytomegalovirus immediate-early 1 protein. Journal of Virology 65:4812–4820
   [Google Scholar]
2. Alper C. A., Kruskall M. S., Marcus-Bagley D., Craven D. E., Katz A. J., Brink S. J., Dienstag J. L., Awdeh Z., Yunis E. J. 1989; Genetic prediction of nonresponse to hepatitis B vaccine. New England Journal of Medicine 321:708–712
   [Google Scholar]
3. Balfour H. H., Welo P. K., Sachs G. W. 1976; Cytomegalovirus vaccine trial in 400 renal transplant candidates. Transplantation Proceedings 17:81
   [Google Scholar]
4. Beck S., Barrell B. G. 1988; Human cytomegalovirus encodes a glycoprotein homologous to MHC class I antigens. Nature 331:269–272
   [Google Scholar]
5. Borysiewicz L. K., Hickling J. C., Graham S., Sinclair J., Cranage M. P., Smith G. L., Sissons J. G. P. 1988; Human cytomegalovirus specific cytotoxic T cells: relative frequency of stage-specific CTL recognizing the 72kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. Journal of Experimental Medicine 168:919–932
   [Google Scholar]
6. Britt W. J. 1991; Recent advances in the identification of significant human cytomegalovirus-encoded proteins. Transplantation Proceedings 23:64–69
   [Google Scholar]
7. Browne H., Churcher M., Minson T. 1992; Construction and characterization of a human cytomegalovirus mutant with the UL18 (class I homolog) gene deleted. Journal of Virology 66:6784–6787
   [Google Scholar]
8. Chicz R. M., Urban R. G., Gorga J. C., Vignali D. A. A., Lane W. S., Strominger R. L. 1993; Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. Journal of Experimental Medicine 178:27–47
   [Google Scholar]
9. Davis M. G., Kenney S. C., Kamine J., Pagano J. S., Huang E. S. 1987; Immediate-early gene region of human cytomegalovirus trans-activates the promoter of human immunodeficiency virus. Proceedings of the National Academy of Sciences, USA 84:8642–8646
   [Google Scholar]
10. Del Val M., Schlicht H., Volkmer H., Messerle M., Reddehase M. J., Koszinowski U. H. 1991; Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. Journal of Virology 65:3641–3646
    [Google Scholar]
11. Fujinami R. S., Nelson J. A., Walker L., Oldstone M. B. A. 1988; Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DRB chain: a means for graft rejection and immunosuppression. Journal of Virology 62:100–105
    [Google Scholar]
12. Gilbert M. J., Riddell S. R., Greenberg P. D. 1993; Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. Journal of Immunology 67:3461–3469
    [Google Scholar]
13. Greenberg P., Goodrich J., Riddell S. R. 1991a; Adoptive immunotherapy of human cytomegalovirus infection: potential role in protection from disease progression. Transplantation Proceedings 23:97–101
    [Google Scholar]
14. Greenberg P. D., Reusser P., Goodrich J. M., Riddell S. R. 1991b; Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded in vitro. Annals of the New York Academy of Sciences 636:184–195
    [Google Scholar]
15. Griffiths P. D., Grundy J. E. 1987; Molecular biology and immunology of cytomegalovirus. Biochemistry Journal 241:313–324
    [Google Scholar]
16. Grundy J. E. 1991; Cytomegalovirus vaccines. In Vaccines and Immunotherapy pp 351–356 Edited by Cryzs J. S. J. New York: Pergamon Press;
    [Google Scholar]
17. Ho M. 1990; Epidemiology of cytomegalovirus infections. Reviews of Infectious Diseases 12: Supplement 7S701–710
    [Google Scholar]
18. John G., Scholl B.-C., Traupe B., Fleckenstein B. 1987; The two major structural phosphoproteins (pp65 and ppl50) of human cytomegalovirus and their antigenic properties. Journal of General Virology 68:1327–1337
    [Google Scholar]
19. Jonjic S., Pavic I., Lucin P., Rukavina D., Koszinowski U. H. 1990; Efficacious control of cytomegalovirus infection after longterm depletion of CD8⁺ T lymphocytes. Journal of Virology 64:5457–5464
    [Google Scholar]
20. Kniskern P. J., Miller W. J. 1992; Hepatitis B vaccines: blueprints for vaccines of the future. In Vaccines: New Approaches to Immunological Problems pp 177–204 Edited by Elliss R. W. Boston: Butterworth-Heinemann;
    [Google Scholar]
21. Lindsley M. D., Torpey D. J. III, Rinaldo C. R. JR 1986; HLA-DR-restricted cytotoxicity of cytomegalovirus-infected monocytes mediated by Leu-3-positive T cells. Journal of Immunology 136:3045–3051
    [Google Scholar]
22. Liu B., Stinski M. F. 1992; Human cytomegalovirus contains a tegument protein that enhances transcription from promoters with upstream ATF and AP-1 cis-acting elements. Journal of Virology 66:4434–4444
    [Google Scholar]
23. Liu Y. N., Kari B., Gehrz R. C. 1988; Human immune response to major human cytomegalovirus glycoprotein complexes. Journal of Virology 62:1066–1070
    [Google Scholar]
24. Liu Y.-N., Curtsinger J., Donahue P. R., Klaus A., Optiz G., Cooper J., Karr R. W., Bach F. H., Gehrz R. C. 1993; Molecular analysis of the immune response to human cytomegalovirus glycoprotein B. I. Mapping of HLA-restricted helper T cell epitopes on gp93. Journal of General Virology 74:2207–2214
    [Google Scholar]
25. Maina C. V., Riggs P. D., Grandea A. G. I., Slatko B. E., Moran L. S., Tagliamonte J. A., McReynolds L. A., Guan C. 1988; A vector to express and purify foreign proteins in Escherichia coli by fusion to, and separation from, maltose binding protein. Gene 74:365–373
    [Google Scholar]
26. Marshall G. S., Rabalais G. P., Stout G. G., Waldeyer S. L. 1992; Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. Journal of Infectious Disease 165:381–384
    [Google Scholar]
27. Morel P. A., Chang H. J., Wilson J. W., Conte C., Saidman S. L., Bray J. D., Tweardy D. J. JR, Medsger T. A. 1994; Severe systemic sclerosis with anti-topoisomerase I antibodies is associated with an HLA-DRwll allele. Human Immunology 40:101–110
    [Google Scholar]
28. Plotkin S. A. 1991; Cytomegalovirus vaccine development - past and present. Transplantation Proceedings 23:85–89
    [Google Scholar]
29. Plotkin S. A., Farquar J., Hornberger E. 1976; Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. Journal of Infectious Diseases 134:470–475
    [Google Scholar]
30. Quinnan G. V. J., Burns W. H., Kirmani N., Rook A. H., Manischewitz J., Jackson L., Santos G. W., Saral R. 1984; HLA-restricted cytotoxic T lymphocytes are an early immune response and important defense mechanism in cytomegalovirus infection. Reviews of Infectious Diseases 6:156–163
    [Google Scholar]
31. Rammensee H. G., Falk K., Rotzschke O. 1993; MHC molecules as peptide receptors. Current Opinion in Immunology 5:35–44
    [Google Scholar]
32. Rasmussen L. 1990; Immune response to human cytomegalovirus infection. Current Topics in Microbiology and Immunology 154:221–254
    [Google Scholar]
33. Rasmussen L., Morris S., Wolitz R., Dowling A., Fessell J., Holodniy M., Merrigan T. 1994; Deficiency in antibody responses to human cytomegalovirus glycoprotein gH in human immunodeficiency virus-infected patients at risk for cytomegalovirus retinitis. Journal of Infectious Diseases 170:673–677
    [Google Scholar]
34. Riddell S. R., Watanabe K. S., Goodrich J. M., Li C. R., Agha M. E., Greenberg P. D. 1992; Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238–241
    [Google Scholar]
35. Spaete R. R. 1991; A recombinant subunit vaccine approach to HCMV vaccine development. Transplantation Proceedings 23:90–96
    [Google Scholar]
36. Spaete R. R., Thayer R. M., Probert W. S., Masiarz F. R., Chamberlain S. H., Rasmussen L., Merigan T. C., Pachl C. 1988; Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology 167:207–225
    [Google Scholar]
37. Thomsen D. R., Stinski M. F. 1981; Cloning of the human cytomegalovirus genome as endonuclease Xbal fragments. Gene 16:207–216
    [Google Scholar]